Alzamend Neuro (ALZN) Selling, General & Administrative (2020 - 2026)
Powered by 
Analysis
Alzamend Neuro (ALZN) Selling, General & Administrative (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.94 Bn | 195.95 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 179.74 Bn | 176.57 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 132.05 Bn | 124.20 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.43 Bn | 74.44 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 61.23 Bn | 56.04 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 53.42 Bn | 48.28 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.77 Bn | 30.47 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | 2.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 2.44 Mn |
| Jan 31, 2026 | 919,025.00 |
| Oct 31, 2025 | 821,826.00 |
| Jul 31, 2025 | 959,334.00 |
| Apr 30, 2025 | 688,779.00 |
| Jan 31, 2025 | 590,304.00 |
| Oct 31, 2024 | 1.05 Mn |
| Jul 31, 2024 | 755,834.00 |
| Apr 30, 2024 | 666,634.00 |
| Jan 31, 2024 | 751,173.00 |
| Oct 31, 2023 | 904,939.00 |
| Jul 31, 2023 | 1.16 Mn |
| Apr 30, 2023 | 1.66 Mn |
| Jan 31, 2023 | 2.53 Mn |
| Oct 31, 2022 | 1.57 Mn |
| Jul 31, 2022 | 1.66 Mn |
| Apr 30, 2022 | 2.21 Mn |
| Jan 31, 2022 | 1.68 Mn |
| Oct 31, 2021 | 1.83 Mn |
| Jul 31, 2021 | 1.39 Mn |